Join Andelyn’s Newsletter
Your Source for Quality Insights on Cell and Gene Therapies
We are committed to advancing the future of cell and gene therapies. By subscribing to our newsletter, you’ll receive:
Expert perspectives on the latest industry developments
Educational content on therapies from concept to commercialization
Exclusive insights into our pioneering work in rare diseases
Updates on conference attendance and technical presentations
News & Press Releases
May 12, 2025
Andelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after DiagnosisAndelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after DiagnosisPress Release
May 6, 2025
Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.Press Release
February 18, 2025
Andelyn Biosciences Expands AAV Curator™ Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and HarvardAndelyn Biosciences Expands AAV Curator™ Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and HarvardPress Release
View All News & Press Releases